Skip to main content
. 2019 Feb 14;11:1517–1524. doi: 10.2147/CMAR.S176762

Figure 1.

Figure 1

The disease-free survival rates of all patients and non-metastatic patients.

Notes: (A) All patients (low Plk3 expression [N=324, 65%], high Plk3 expression [N=167, 33%]) and (B) non-metastatic patients (low Plk3 expression [N=292, 58%], high Plk3 expression [N=158, 32%]) with prostate cancer were compared according to low- and high-Plk3 status. Statistical significance was determined using the log-rank test.

Abbreviation: Plk3, polo-like kinase 3.